Bio-Path Holdings, Inc. · OTC:BPTH
Bio-Path — Investor Presentation (July 2017)
22 slides from Bio-Path's investor presentation, July 2017

Slide 1: Company Presentation July 2017
Company Presentation July 2017 “A new path in DNA-powered medicine” 1

Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

Slide 3: DNAbilize Technology
DNAbilize™ Technology ✓ Enables the development and delivery of systemic antisense DNA treatments for a broad spectrum of cancers including hematological malignancies, solid tumors, as well as diseases outside of cancer ➢ has been the only technology in therapeutic applications that has shown no evi

Slide 4: Investment Highlights
Investment Highlights • Advanced oligonucleotide therapeutics with high efficiency delivery Broad Vision, Focused • New composition and methods of use patents filed to cover DNAbilize™ Strategy technology solely owned by Bio-Path • Lead candidate prexigebersen in Phase II for acute myeloid leukemia

Slide 5: DNAbilize Antisense and Technology Profile: A Targeted Method for Treating Disease
DNAbilize™ Antisense and Technology Profile: A Targeted Method for Treating Disease ➢ Antisense - molecules that interfere with the process of producing proteins inside cells (RNAi) ➢ Does not use a toxic agent to kill cells, but blocks production of proteins ➢ Advantage of specificity because it ta

Slide 6: DNAbilize Technology Summary
DNAbilize™ Technology Summary DNAbilize™ Technology is a proprietary antisense and delivery platform that solves the antisense industry dilemma SAFE: No toxicity from the DNA modification or the lipid delivery, no platelet or hepatic toxicity SYSTEMIC: Allows for systemic distribution via IV infusio

Slide 7: Clinical Pipeline
Clinical Pipeline Target Indications Preclinical IND Phase I Phase II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen Solid (BP1001) tumors BP1002 (Liposomal Bcl2) Lymphoma DNAbilize™ Technology Ready to out-license *Prexigebersen (BP1001) has received orphan drug designation f

Slide 8: Continuing Improvement in Product Design and Manufacturing
Continuing Improvement in Product Design and Manufacturing Scale up 2nd Going Forward CMC’s IND Manufacturing Development from initial Generation • Lyo process Lead Product batch size Formulation • Capacity • New assays • Process • High oligo • Lyo cycle • Oligo loading properties • Capacity increas

Slide 9: Manufacturing Improvements
Manufacturing Improvements ➢ Through our dose-escalating Phase 1 trial we upgraded our supplier base with the goal of increased capability and capacity ➢ Improved capabilities and operating efficiencies affected important drug properties, result being the need to re-optimize manufacturing ➢ We are d

Slide 10: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia
DNAbilize™ Lead Target and Indications: Grb2 and Myeloid Leukemia Prexigebersen (BP1001) is an antisense DNA to the bridging protein Grb2 ❖ Ideal target for myeloid leukemia because it shuts down the Ras pathway in receptor activated myeloid cells without exerting adverse effects on Ras signaling th

Slide 11: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen
Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen ➢ AML, CML, & MDS Patients Refractory or Resistant to Current Therapies ➢ Patients averaged 6 prior therapies ➢ Dose escalating treatment cycle, 8 doses over 4 weeks, up to 90 mg/m2 ➢ Average reduction in circulating blasts was

Slide 12: Prexigebersen Down-regulates Grb2 Protein in Target Cells
Prexigebersen Down-regulates Grb2 Protein in Target Cells Grb2 levels decreased in 11 of 13 patient samples by end of treatment (EOT) pErk levels decreased in 7 of 13 patient samples by EOT 2 2 NS1 = no sample collected 2Fewer cells used in analysis because sample had less cells 12

Slide 13: Response to Treatment for Blast Crisis CML and Stable Disease in AML
Response to Treatment for Blast Crisis CML and Stable Disease in AML • Patient 002: 32 year-old, Hispanic male with myeloid blast crisis of CML • Prior therapies consisted of: ― Gleevec ― Dasatinib ― Nilotinib ― DCC-2036 ― Cytarabine/Fludarabine/ ― Dasatinib/Gemtuzumab ― PHA-739358 ― Clofarabine/Das

Slide 14: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results
Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results Relapsed/refractory AML patients - 3 evaluable patients in each of 2 cohorts - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks 5 of 6 patients responded: - 3 patients achieved complete remission - 2

Slide 15: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy
Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Safety segment completed, demonstrated no negative synergies using prexigebersen together with frontline therapy (LDAC) – Treatment of de novo AML patients who are induction therapy ineligible and unfit for a stem cel

Slide 16: Advances in the CML Program
Advances in the CML Program • Presentation at the 58th American Society of Hematology Annual Meeting: – BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia • Prexigebersen decreased the proliferation of Gleevec® (imatinib)-resistant CML cells in a dose-dependent manner • Prexigebersen pretr

Slide 17: Prexigebersen Treatment Paradigm
Prexigebersen Treatment Paradigm • Frontline therapy for de novo AML patients who are induction therapy ineligible and unfit for a stem cell transplant – Prexigebersen combination with LDAC – Current response rate frontline therapy alone less than 20% – Prexigebersen to improve response rates signif

Slide 18: Preclinical Pipeline
Preclinical Pipeline Validating DNAbilize™ with Key Opinion Leaders: • Establishing prexigebersen in triple negative and inflammatory breast cancer and advanced ovarian cancer with the MD Anderson Cancer Center – Advances in liposome properties enhancing solid tumor outcomes • Developing clinical an

Slide 19: Achievements and Upcoming Milestones
Achievements and Upcoming Milestones Recent Accomplishments: Value propositions being advanced: • Potential for switch to registration trial for On target to complete enrollment of the accelerated approval after the interim analysis first 19 patients for the interim analysis for of the first 19 pa

Slide 20: Leadership
Leadership Peter Nielsen Co-Founder, President, Chief Executive Officer and Chief Financial Officer • Officer and Director since founding Company in 2007 • Manufacturing development and evolution of engineered product design Ulrich Mueller, PhD Chief Operating Officer • Previously Vice President at

Slide 21: Scientific Advisory Board
Scientific Advisory Board Jorge Cortes, M.D. Chairman • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department of Leukemia at The University of T

Slide 22: IP and Financial Snapshot
IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patents filed to cover DNAbilize™ technology, solely owned by Bio-Path Financial Snapshot • Ticker: NASDAQ: BPTH • Cash: $7.1 million as of March 31, 2017 • $10 million r
Source: Internet Archive copy of biopathholdings.com
More decks from Bio-Path Holdings, Inc.
Investor Presentation (May 2022)12 slides · May 2022
Investor Presentation (January 2022)17 slides · January 2022
Investor Presentation (March 2021)17 slides · March 2021
Shareholder Meeting (December 2020)16 slides · Dec 21, 2020
Investor Presentation (May 2019)23 slides · May 2019
Investor Presentation (October 2017)20 slides · October 2017